New GLP-1 agonist dulaglutide improves metabolic dysfunction and extenuates development of non-acoholic steatohepatitis in miceHepatitis delta is a major health problem, not only because of the severity of the disease, but also due to the lack of effective antiviral treatment. To improve the ...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the
We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects. Selective chemical modification to glucagon resulted in a loss of specificity, with minimal chan
Zepbound (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for weight reduction in adults with obesity or adults with overweight, and severe obstructive sleep apnea in adults with obesity. FDA Approves Zepbound...
Introduction: A fixed combination of basal insulin degludec and glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (IDegLira; 50 units degludec/1.8 mg liraglutide) has been developed as a once daily injection for the treatment of type 2 diabetes (T2D). In the phase 3a trial program...
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1
Heightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists Tyrone A. Johnson, MD; Michael A. Incze, MD, MSEd; William K. Silverstein, MD, MSc JAMA Intern Med Antihypertensive Medications in Patients With Weight Loss—Reply Kagan E. Karakus, MD; Viral N. Shah, MD...
Pfizer announced early Thursday morning that it has selected its preferred once-daily modified release formulation of danuglipron, a move that it said was a significant milestone in the obesity drug’s development. Danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor...
(75 mmol/mol) and a mean baseline body weight of 96.4 kg [104]. Moreover, promising results with orforglipron [105], a nonpeptide oral GLP-1 RA were also presented at the CVOT Summit. At week 26, there was a significant change in mean placebo adjusted HbA1c (-1.67%) and body...
5.2. GLP-1 receptor agonist GLP-l receptor agonizts are another kind of new therapeutic drug for DKD [90]. GLP-1 is a hormone produced through the intestinal tract that binds to GLP-1 receptors in the pancreas, stimulating insulin production and inhibiting glucagon production in the glucose-...